Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Iris W.J.M. van Goor

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3770-9841; OpenAlex author ID A5091198705. Sources: OpenAlex.

Their work

Papers
21 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 7 papers · 2025: 3 papers · 2026: 6 papers

Papers 21

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. First author DOI 10.1016/j.ejso.2025.111165↗
  3. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  4. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  5. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-025-18639-1↗
  6. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-025-18791-8↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. First author DOI 10.1001/jamasurg.2024.5024↗
  8. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  9. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  10. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  11. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  12. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  13. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… First author DOI 10.1186/s13063-024-08223-5↗
  14. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… First author DOI 10.1186/s13063-024-08295-3↗
  15. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. First author DOI 10.1245/s10434-024-15070-w↗
  16. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  17. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  18. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, obs… Co-author DOI 10.1093/bjsopen/zrac174↗
  19. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  20. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  21. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. First author DOI 10.1016/j.ejso.2020.11.145↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lois A. Daamen · 20 shared papers, 2021–2026 · strength 3.29
  2. Izaak Quintus Molenaar · 20 shared papers, 2021–2026 · strength 3.29
  3. Hjalmar C. van Santvoort · 20 shared papers, 2021–2026 · strength 3.29
  4. Marc G. Besselink · 18 shared papers, 2021–2026 · strength 2.94
  5. Bas Groot Koerkamp · 16 shared papers, 2021–2026 · strength 2.64
  6. Martijn W.J. Stommel · 14 shared papers, 2021–2026 · strength 2.30
  7. Ignace H. J. T. de Hingh · 14 shared papers, 2021–2026 · strength 2.22
  8. Paul C. M. Andel · 12 shared papers, 2024–2026 · strength 2.15
  9. Martijn Intven · 13 shared papers, 2021–2026 · strength 2.07
  10. Vincent Erwin de Meijer · 12 shared papers, 2021–2026 · strength 1.95
  11. Sebastiaan Festen · 12 shared papers, 2021–2026 · strength 1.93
  12. Geert Kazemier M · 11 shared papers, 2021–2026 · strength 1.80
  13. Robert C. Verdonk · 10 shared papers, 2024–2026 · strength 1.73
  14. Thijs J. Schouten · 10 shared papers, 2021–2026 · strength 1.72
  15. Bert A. Bonsing · 10 shared papers, 2021–2026 · strength 1.65
  16. Gert J. Meijer · 10 shared papers, 2022–2026 · strength 1.64
  17. Vincent P. Groot · 8 shared papers, 2023–2026 · strength 1.45
  18. Vincent B. Nieuwenhuijs · 7 shared papers, 2021–2026 · strength 1.17
  19. Joseph R. Habib · 6 shared papers, 2023–2026 · strength 1.09
  20. Johanna W. Wilmink · 6 shared papers, 2022–2026 · strength 0.97
  21. Ammar A. Javed · 5 shared papers, 2024–2026 · strength 0.93
  22. Geertjan van Tienhoven · 6 shared papers, 2022–2026 · strength 0.91
  23. Lodewijk A.A. Brosens · 6 shared papers, 2021–2024 · strength 0.88
  24. Casper H.J. van Eijck · 5 shared papers, 2023–2026 · strength 0.81
  25. Gijs A. Patijn · 5 shared papers, 2023–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.